Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
373
datasets available to search
ShareScore release 0.9.0
Dataset results
373 results for “Chronic myeloid leukemia”
Metabolic shift of chronic myeloid leukemia patients under Imatinib-Pioglitazone regimen and discontinuation_dataset
<p>The EDI-PIO (<strong>E</strong>studo de <strong>D</strong>escontinuação de <strong>I</strong>matinibe após<strong> Pio</strong>glitazona) is a single-center, longitudinal, prospective, phase 2, non-randomized, open, clinical trial (NCT02852486, August 2, 2016 retrospectively registered) for the discontinuation of imatinib after concomitant use of pioglitazone, being the first of its kind in a Brazilian population with chronic myeloid leukemia. Due to remaining of leukemic quiescent cells that are not affected by tyrosine kinase inhibitors, it has been suggested the use of pioglitazone, a PPARγ agonist, together with imatinib as a strategy for the maintenance of deep molecular response. The clinical benefit to this association is still controversial, and the metabolic alteration along this process remains unclear. Therefore, we applied a metabolomic protocol using high-resolution mass spectrometry to profile plasmatic metabolic response of a prospective cohort of 10 individuals under discontinuation of imatinib and pioglitazone protocol. By comparing patients under pioglitazone and imatinib treatment with imatinib monotherapy and discontinuation phase, we were able to annotate 41 and 36 metabolites, respectively. The metabolic alterations observed during Imatinib-Pioglitazone combined therapy are associated with an extensive lipid remodelling, with activation of β-oxidation pathway, in addition to the presence of markers that suggest mitochondrial dysfunction.</p>
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
<p>This repository contains CITE-seq data generated from CML stem and progenitor cells before and after hydroxyurea treatment using the BD Rhapsody Single-Cell Analysis System. </p> <p><strong><br>File descriptions:</strong></p> <p>1. RSEC-adjusted UMI count files generated using the BD Rhapsody Targeted Analysis Pipeline (v. 1.10.1):</p> <ul> <li>CartridgeS1_RSEC_MolsPerCell.csv</li> </ul> <p>2. RSEC-adjusted UMI counts for cells remaining after cell quality filtering using SeqGeq software (genes expressed vs library size):</p> <ul> <li>CartridgeS1_RSEC_MolsPerCell_postQC.csv</li> </ul> <p>3. Sample tag (sample of origin) calls for each putative cell, outputted by the BD Rhapsody Targeted Analysis Pipeline (v. 1.10.1). </p> <ul> <li>CartridgeS1_Sample_Tag_Calls.csv</li> </ul> <p> </p>
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
ClinicalTrials.gov study NCT03578367. IPD Sharing: YES. Countries: 15. Publications: 1.
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
ClinicalTrials.gov study NCT02467270. IPD Sharing: YES. Countries: 21. Publications: 2.
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov study NCT01667133. IPD Sharing: YES. Countries: 1. Publications: 2.
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
ClinicalTrials.gov study NCT01207440. IPD Sharing: YES. Countries: 11. Publications: 5.
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
ClinicalTrials.gov study NCT00375219. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
ClinicalTrials.gov study NCT02228382. IPD Sharing: YES. Countries: 8. Publications: 5.
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
ClinicalTrials.gov study NCT01904136. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
ClinicalTrials.gov study NCT00101816. IPD Sharing: Not stated. Countries: 20. Publications: 2.
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
ClinicalTrials.gov study NCT02092324. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
ClinicalTrials.gov study NCT00449761. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
ClinicalTrials.gov study NCT01850004. IPD Sharing: Not stated. Countries: 6. Publications: 1.
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
ClinicalTrials.gov study NCT00313586. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
ClinicalTrials.gov study NCT01650805. IPD Sharing: Not stated. Countries: 24. Publications: 2.
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
ClinicalTrials.gov study NCT00101647. IPD Sharing: Not stated. Countries: 23. Publications: 2.
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
ClinicalTrials.gov study NCT00101660. IPD Sharing: Not stated. Countries: 22. Publications: 2.
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
ClinicalTrials.gov study NCT01593254. IPD Sharing: Not stated. Countries: 15. Publications: 1.
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
ClinicalTrials.gov study NCT01254188. IPD Sharing: Not stated. Countries: 19. Publications: 1.
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
ClinicalTrials.gov study NCT00124748. IPD Sharing: Not stated. Countries: 6. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.